Literature DB >> 26399962

Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.

J Fernando Arevalo1,2, Andres F Lasave3, Vishali Gupta2, Igor Kozak2, Mosa Barakat Al Harbi1, Abdulaziz Adel Al Rushood2, Hassan A Al Dhibi2.   

Abstract

PURPOSE: To describe the clinical characteristics and treatment outcomes of Vogt-Koyanagi-Harada (VKH) disease over a 12-year period.
METHODS: A retrospective chart review was used to identify VKH patients, from January 1999 to December 2011.
RESULTS: In total, 154 patients (308 eyes) were diagnosed with VKH. The mean age at diagnosis was 33.8 ± 13 years. Mean baseline best-corrected visual acuity (BCVA) was 20/125; (0.8 ± 0.6 logMAR). Recurrent episodes occurred in 107 (54%) patients. Oral prednisone was administered in all patients. At the last visit, the mean BCVA was 20/50 (0.4 ± 0.7 logMAR). The most common complications post-treatment were: glaucoma [104 (33.8%) eyes] and cataract [84 (27.2%) eyes].
CONCLUSIONS: In Saudi Arabia, VKH-related uveitis is predominant in young females. Bilateral panuveitis is the most common ocular manifestation and near 50% of eyes present with exudative retinal detachment. Oral prednisone was the primary treatment and the majority of eyes maintained 20/50 or better vision.

Entities:  

Keywords:  Panuveitis; Saudi Arabia; Vogt–Koyanagi–Harada disease; prednisone; uveitis

Mesh:

Substances:

Year:  2015        PMID: 26399962     DOI: 10.3109/09273948.2015.1025984

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  8 in total

1.  High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease.

Authors:  Carlos Alvarez-Guzman; Jorge E Valdez-Garcia; Raul E Ruiz-Lozano; Alejandro Rodriguez-Garcia; Carlos F Navas-Villar; Curt Hartleben-Matkin; Miguel Pedroza-Seres
Journal:  Int Ophthalmol       Date:  2022-07-05       Impact factor: 2.031

2.  Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy.

Authors:  Rui Fushitsu; Akihiro Ishibazawa; Masataka Murono; Reiko Kinouchi
Journal:  Int Ophthalmol       Date:  2022-07-22       Impact factor: 2.029

3.  Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.

Authors:  Elizabeth Shen; Sivakumar R Rathinam; Manohar Babu; Anuradha Kanakath; Radhika Thundikandy; Salena M Lee; Erica N Browne; Travis C Porco; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2016-06-10       Impact factor: 5.258

Review 4.  Eclectic Ocular Comorbidities and Systemic Diseases with Eye Involvement: A Review.

Authors:  María D Pinazo-Durán; Vicente Zanón-Moreno; José J García-Medina; J Fernando Arévalo; Roberto Gallego-Pinazo; Carlo Nucci
Journal:  Biomed Res Int       Date:  2016-03-14       Impact factor: 3.411

Review 5.  Vogt-Koyanagi-Harada syndrome - current perspectives.

Authors:  Abeir Baltmr; Sue Lightman; Oren Tomkins-Netzer
Journal:  Clin Ophthalmol       Date:  2016-11-24

6.  Clinical spectrum and management options in Vogt-Koyanagi-Harada disease.

Authors:  Sikander Ak Lodhi; Jm Lokabhi Reddy; Venkataratnam Peram
Journal:  Clin Ophthalmol       Date:  2017-08-07

7.  Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: a report of two cases.

Authors:  Moustafa S Magliyah; Abdulmajeed S Al-Fakhri; Hassan A Al-Dhibi
Journal:  BMC Ophthalmol       Date:  2020-12-01       Impact factor: 2.209

8.  Phacoemulsification after trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease: intermediate-term visual outcome, IOP control and trabeculectomy survival.

Authors:  Faisal A Almobarak; Ali H Alharbi; Ibrahim Aljadaan; Hassan Aldhibi
Journal:  BMC Ophthalmol       Date:  2022-05-09       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.